-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$32.00115.2% Upside
Cadrenal Therapeutics, Inc. Common Stock Frequently Asked Questions
-
What analysts cover Cadrenal Therapeutics, Inc. Common Stock?
Cadrenal Therapeutics, Inc. Common Stock has been rated by research analysts at H.C. Wainwright in the past 90 days.